의학물리학

본문글자크기
  • [Oncotarget.] Estimation of the risk of secondary malignancy arising from whole-breast irradiation: comparison of five radiotherapy modalities, including TomoHDA.

    강동경희대병원/한은영, 김동욱*

  • 출처
    Oncotarget.
  • 등재일
    2016 Mar 26.
  • 저널이슈번호
    doi: 10.18632/oncotarget.8392.
  • 내용

    바로가기  >

    Abstract

    The risk of secondary cancer from radiation treatment remains a concern for long-term breast cancer survivors, especially those treated with radiation at the age younger than 45 years. Treatment modalities optimally maximize the dose delivery to the tumor while minimizing radiation doses to neighboring organs, which can lead to secondary cancers. A new TomoTherapy treatment machine, TomoHDATM, can treat an entire breast with two static but intensity-modulated beams in a slice-by-slice fashion. This feature could reduce scattered and leakage radiation doses. We compared the plan quality and lifetime attributable risk (LAR) of a second malignancy among five treatment modalities: three-dimensional conformal radiation therapy, field-in-field forward-planned intensity-modulated radiation therapy, inverse-planned intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy, and TomoDirect mode on the TomoHDA system. Ten breast cancer patients were selected for retrospective analysis. Organ equivalent doses, plan characteristics, and LARs were compared. Out-of-field organ doses were measured with radio-photoluminescence glass dosimeters. Although the IMRT plan provided overall better plan quality, including the lowest probability of pneumonitis, it caused the second highest LAR. The TomoTherapy plan provided plan quality comparable to the IMRT plan and posed the lowest total LAR to neighboring organs. Therefore, it can be a better treatment modality for younger patients who have a longer life expectancy. 

     

    Author information

    Han EY1, Paudel N2, Sung J3, Yoon M3, Chung WK4, Kim DW4.

    1Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

    2Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

    3Department of Bio-Convergence Engineering, Korea University, Seoul, Korea.

    4Department of Radiation Oncology, Kyung Hee University Hospital at Gangdong, Seoul, Korea. 

  • 키워드
    IMRT; TomoHDA; VMAT; breast; secondary malignancy
  • 덧글달기
    덧글달기
       IP : 54.242.22.247

    등록